Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing

被引：147

作者：

Martin, M. A. ^{[1
]}

Klein, T. E. ^{[2
]}

Dong, B. J. ^{[3
]}

Pirmohamed, M. ^{[4
]}

Haas, D. W. ^{[5
,6
,7
]}

Kroetz, D. L. ^{[1
]}

机构：

[1] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA

[2] Stanford Univ, Dept Genet, Stanford, CA 94305 USA

[3] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94143 USA

[4] Univ Liverpool, Dept Pharmacol, Liverpool L69 3BX, Merseyside, England

[5] Vanderbilt Univ, Dept Med, Nashville, TN USA

[6] Vanderbilt Univ, Dept Pharmacol, Nashville, TN USA

[7] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Nashville, TN USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2012年 / 91卷 / 04期

基金：

美国国家卫生研究院;

关键词：

HUMAN-LEUKOCYTE ANTIGEN-B-ASTERISK-5701; HYPERSENSITIVITY REACTIONS; DRUG HYPERSENSITIVITY; MYOCARDIAL-INFARCTION; HLA-B-ASTERISK-5701; THERAPY; ASSOCIATION; HIV-1; MARKER; B-ASTERISK-5701;

D O I：

10.1038/clpt.2011.355

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Human leukocyte antigen B (HLA-B) is responsible for presenting peptides to immune cells and plays a critical role in normal immune recognition of pathogens. A variant allele, HLA-B(star)57:01, is associated with increased risk of a hypersensitivity reaction to the anti-HIV drug abacavir. In the absence of genetic prescreening, hypersensitivity affects similar to 6% of patients and can be life-threatening with repeated dosing. We provide recommendations (updated periodically at http://www.pharmkgb.org) for the use of abacavir based on HLA-B genotype.

引用

页码：734 / 738

页数：5

共 40 条

[1] Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America
Aberg, Judith A.
Kaplan, Jonathan E.
Libman, Howard
Emmanuel, Patricia
Anderson, Jean R.
Stone, Valerie E.
Oleske, James M.
Currier, Judith S.
Gallant, Joel E.
[J]. CLINICAL INFECTIOUS DISEASES, 2009, 49 (05) : 651 - 681
[2] Delayed drug hypersensitivity: models of T-cell stimulation
Adam, Jacqueline
Pichler, Werner J.
Yerly, Daniel
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (05) : 701 - 707
[3] Almeida CAM, 2008, ANTIVIR THER, V13, P281
[4] [Anonymous], GUID US ANT AG HIV 1
[5] Becquemont L, 2011, PHARMACOGENOMICS, V12, P113, DOI [10.2217/pgs.10.147, 10.2217/PGS.10.147]
[6] Abacavir Use and Risk of Acute Myocardial Infarction and Cerebrovascular Events in the Highly Active Antiretroviral Therapy Era
Bedimo, Roger J.
Westfall, Andrew O.
Drechsler, Henning
Vidiella, Gabriela
Tebas, Pablo
[J]. CLINICAL INFECTIOUS DISEASES, 2011, 53 (01) : 84 - 91
[7] Human leukocyte antigens and drug hypersensitivity
Chung, Wen-Hung
Hung, Shuen-Lu
Chen, Yuan-Tsong
[J]. CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 7 (04) : 317 - 323
[8] A marker for Stevens-Johnson syndrome
Chung, WH
Hung, SI
Hong, HS
Hsih, MS
Yang, LC
Ho, HC
Wu, JY
Chen, YT
[J]. NATURE, 2004, 428 (6982) : 486 - 486
[9] Mechanisms of MHC class I-restricted antigen processing and cross-presentation
Cresswell, P
Ackerman, AL
Giodini, A
Peaper, DR
Wearsch, PA
[J]. IMMUNOLOGICAL REVIEWS, 2005, 207 : 145 - 157
[10] HLA-B☆5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
Daly, Ann K.
Donaldson, Peter T.
Bhatnagar, Pallav
Shen, Yufeng
Pe'er, Itsik
Floratos, Aris
Daly, Mark J.
Goldstein, David B.
John, Sally
Nelson, Matthew R.
Graham, Julia
Park, B. Kevin
Dillon, John F.
Bernal, William
Cordell, Heather J.
Pirmohamed, Munir
Aithal, Guruprasad P.
Day, Christopher P.
[J]. NATURE GENETICS, 2009, 41 (07) : 816 - U71

← 1 2 3 4 →